Montelukast Indoco

Montelukast, the active ingredient in Montelukast Indoco, is a leukotriene receptor antagonist presented as a tablet for oral use. It is prescribed to manage asthma, exercise‑induced bronchoconstriction, and allergic rhinitis in adults and children as directed by a healthcare professional. The medication blocks cysteinyl leukotriene receptors in the airways, reducing inflammation and narrowing of the bronchial tubes. Patients should follow the dosing schedule advised by their physician and report any adverse reactions promptly.

GNH USA supplies Montelukast Indoco as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control chronic airway diseases.

Asthma: Improves long‑term control and reduces the frequency of asthma attacks. Exercise‑induced bronchoconstriction: Prevents narrowing of the airways during physical activity. Allergic rhinitis: Alleviates nasal congestion, sneezing and itchy eyes associated with seasonal allergies.

Montelukast is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate headache. - Abdominal pain: stomach discomfort or cramps. - Cough: transient cough. - Nausea: feeling of sickness. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Allergic reactions: rash, swelling, or anaphylaxis. - Neuropsychiatric events: mood changes, depression, or suicidal thoughts. - Liver injury: elevated liver enzymes or hepatitis.

When prescribing Montelukast, clinicians should consider several safety and handling precautions.

- Assess asthma control: confirm that the patient’s asthma is stable before initiating therapy. - Monitor neuropsychiatric symptoms: watch for mood changes, depression, or suicidal ideation. - Use with caution in hepatic impairment: adjust therapy if liver disease is present. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Review concomitant medications: consider potential drug interactions. - Store at ambient temperature: keep in the original packaging, protect from moisture and heat.

Montelukast may interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: enzyme induction may reduce Montelukast plasma levels. - Rifampin: strong CYP3A4 inducer can lower drug exposure. - Ketoconazole: potent CYP3A4 inhibitor may increase Montelukast concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of anticoagulant effect; monitor INR. - Beta‑agonists: additive bronchodilatory effect; adjust dosing if needed. - Other leukotriene modifiers: combined use may increase risk of side effects.